BDX

BCAL FPO [BDX]
BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer. It develops BREASTESTplus, a first-in-class blood test designed to be used alongside standard mammogram in breast cancer screening. The company also develops BREASTEST, BCAL Diagnostics, and BCAL Dx. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
Healthcare · ASX Small Cap
$0.0650 +0.0%

Updated 9 Sep 2026 · Signals refresh every scan

Appeared in 2 consecutive scansFirst seen: 2026-02-25
Get alerts when BDX triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track BDX — Free

Active Signals

Bullish Signals

  • Watch out — volume is flowing out even as price holds up. Distribution pattern
  • Drifting lower — down 5.8% over the last 5 days
  • Beating the Small Ords index — relative strength of 1.19, so it's outpacing the pack
  • Critical cash runway (1.0 quarters)
  • Moderate P/S ratio (10.2x)
  • Near 52-week low (13% of range)
  • Small-cap ($20-100M)
  • CANSLIM S: Tight float (49%)
  • Sentiment is mixed — no strong consensus either way
  • Altman Z-Score distress zone (1.42 < 1.81, low-confidence approx)
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Revenue declining (-15%)
  • Piotroski F-Score weak (2/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 30% over the past year
  • Revenue declining at -15% — the top line is shrinking
  • The bigger volume days are the down days — volume-weighted momentum is negative (-1.36%/day)

Expected next for BDX

27 Oct 2026Quarterly Cash Flow Report (4C)Estimated from past filings
Window: 20 Oct to 3 Nov
The last 8 moved BDX +1.1% on the day, on average — an observation, not a guide to what happens next.
Each date is labelled with how it is known. A date estimated from past filings is inferred from this company's own filing rhythm — it is not a confirmed date and not a statement about what the company intends to do. See the whole ASX calendar →

Recent Catalysts

NONE BCAL Seeks Board Change at Genetic Signatures
NONE Meet The CEO FY 2026 Results Webinar 3 Sept 2026 at 1PM
NONE Appendix 4G and Corporate Governance Statement
LOW Investor Presentation September 2026
LOW Appendix 4E and Annual Report to shareholders

Recent ASX Announcements

2026-09-03 BCAL Seeks Board Change at Genetic Signatures
2026-09-03 Investor Presentation September 2026
2026-08-31 Meet The CEO FY 2026 Results Webinar 3 Sept 2026 at 1PM
2026-08-28 Appendix 4G and Corporate Governance Statement
2026-08-28 Appendix 4E and Annual Report to shareholders PRICE SENSITIVE

Key Metrics

$24.0M
Market Cap
117K
Avg Volume
1.4x
Vol Ratio
$0.05 — $0.15
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-273.3%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandpassFloat: 49%
LLeader vs LaggardlaggardRS: -18
IInstitutional SponsorshipweakInst: 3%
MMarket DirectionneutralNeutral

Sector: Healthcare

110 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
NUZ +37.1%IPD +20.0%HIQ +16.7%AVE +15.0%CVB +11.1%
Compare:BDX vs NUZBDX vs IPDBDX vs HIQ
Share this analysis

Track BDX and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required